Propanc Biopharma, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2019, with fiscal 2018 comparisons. Although the request metadata refers to “2018 Q4,” this filing is an annual report for fiscal 2019, not a quarterly report. Figures are in U.S. dollars unless indicated otherwise.
Business context
Propanc is a pre-revenue, development-stage biotechnology company focused on cancer therapies. Its lead candidate, PRP, is an intravenous combination of the pancreatic proenzymes trypsinogen and chymotrypsinogen, intended for solid tumors, initially including pancreatic and ovarian cancers. PRP remained in preclinical development at year-end; the company had not begun human clinical trials. The FDA granted PRP orphan drug designation for pancreatic cancer.
Financial results and liquidity
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $2.615 million | $3.960 million |
| Loss from operations | $2.615 million | $3.960 million |
| Interest expense | $1.315 million | $2.789 million |
| Net loss | $5.758 million | $7.039 million |
| Net cash used in operating activities | $2.060 million | $2.178 million |
| Cash at fiscal year-end | $2,394 | $19,921 |
- Research and development expense fell to $260,335 from $1.826 million, primarily due to reduced process-development activity. Administration expense rose to $2.326 million from $2.104 million.
- The lower net loss reflected reduced R&D and interest expense, but FY 2019 also included a $2.472 million loss from revaluing derivative liabilities, partly offset by a $1.204 million gain on debt extinguishment and a $115,437 Australian R&D tax benefit.
- At June 30, 2019, total assets were $101,652 and current liabilities were $4.403 million, including $1.657 million of net convertible notes and $698,264 of embedded conversion option liabilities. Working capital deficit was $4.312 million; stockholders’ deficit was $4.301 million; accumulated deficit was $51.041 million.
- Financing provided $2.119 million of cash during FY 2019, including $1.369 million from convertible notes and $1.100 million from common-stock issuances. The company used $2.060 million in operating cash and ended the year with $2,394 in cash.
- The filing reports approximately $1.177 million of convertible-note debt including interest, excluding redemption premium, while the balance sheet reports $1.657 million net carrying value for convertible notes and related accrued interest. These are different measures.
Changes, outlook, and material risks
- Development outlook: Management anticipated submitting a clinical trial application in calendar Q4 2019 and starting a Phase Ib first-in-human study in the first half of 2020, subject to financing and regulatory approval. The proposed study was expected to cost approximately $6.5 million, enroll 20–40 advanced solid-tumor patients, and run for up to 12 months. Phase IIa studies were envisioned afterward; reaching proof of concept was estimated at three to four years. These are plans stated in the filing, not reported achievements.
- Funding and going concern: The auditor and management cited substantial doubt about the company’s ability to continue as a going concern. The company stated it lacked sufficient cash to meet obligations for the next 12 months and depended on additional debt or equity financing. The financial statements include no adjustments for the outcome of this uncertainty.
- Debt and dilution: Convertible notes include conversion prices tied to discounts from recent trading prices; the company said it could not repay principal and interest in cash. It reported 10 notes potentially convertible into approximately 1.81 million shares based on then-applicable conversion prices, and substantial shares reserved for conversions. Further financing may materially dilute shareholders.
- Funding after year-end: The filing describes additional convertible-note financings in July–October 2019, including notes with principal of $78,000, $320,000, $550,000, $131,000 and $108,000. Terms included discounted conversion prices and, in some cases, substantial default interest or premiums. These subsequent financings do not change the June 30, 2019 balance sheet.
- Execution and clinical risks: PRP’s efficacy and safety are unproven in humans. Clinical, manufacturing, regulatory, enrollment, and funding delays or adverse results could prevent or delay commercialization. Propanc relies on outside research and manufacturing providers, including Amatsigroup; it reported $1.689 million spent under the manufacturing agreement and anticipated total payments of $2.5–$5.0 million over three years.
- Controls and governance: Management concluded disclosure controls were ineffective and identified continuing material weaknesses, including undocumented controls, inadequate segregation of duties, no audit committee, and insufficient financial-reporting review and U.S. GAAP expertise. No director was independent at the reporting date.
- Other unusual matters: A former law firm sought $150,000 in fees; a former consultant demanded approximately $400,000 and 60,000 shares. The company disputed both claims; it stated no loss contingency could be estimated for the consultant demand. These claims were reported after fiscal year-end.
- Share structure and trading: A 1-for-500 reverse stock split took effect June 24, 2019. The common stock traded on OTCQB, with limited liquidity and significant price volatility. At October 2, 2019, 1,170,026 common shares were reported outstanding.
Important facts for investors to verify
- Whether the company raised enough capital to meet near-term obligations and fund the planned clinical program, and the current status and terms of its convertible debt.
- Whether the CTA was submitted or approved and whether the Phase Ib trial began; confirm actual trial costs, financing, and regulatory jurisdiction.
- Updated cash, working capital, debt maturities, derivative liabilities, and share counts after subsequent financing and note conversions.
- Progress in remediating the disclosed internal-control weaknesses and establishing independent board and audit oversight.
- Current status and potential financial exposure from the former counsel and consultant disputes.
- Patent status across jurisdictions and whether manufacturing and product supply are ready for clinical use.